HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosmetics Labeling Guidance Under Consideration By CFSAN

This article was originally published in The Rose Sheet

Executive Summary

FDA may issue additional guidance on cosmetic labeling claims in the next several years, according to Office of Cosmetics & Colors Special Assistant to the Director Stanley Milstein, PhD

You may also be interested in...



Cosmetic Claim Review Should Not Make CFSAN Priority Cut – CTFA

Developing a guidance determining the regulatory classification of "cosmetics" versus "drugs" would not be an appropriate use of FDA Center for Food Safety & Applied Nutrition resources, the Cosmetic, Toiletry and Fragrance Association asserts in Aug. 9 comments to the agency addressing the center's fiscal 2005 priorities

Cosmetic Claim Review Should Not Make CFSAN Priority Cut – CTFA

Developing a guidance determining the regulatory classification of "cosmetics" versus "drugs" would not be an appropriate use of FDA Center for Food Safety & Applied Nutrition resources, the Cosmetic, Toiletry and Fragrance Association asserts in Aug. 9 comments to the agency addressing the center's fiscal 2005 priorities

AHA Labeling, CFSAN/CDER MoU Among CFSAN’s Completed Cosmetic Goals

The Center for Food Safety and Applied Nutrition recently renewed a memorandum of understanding with the Center for Drug Evaluation and Research, marking one of two actions completed by the Office of Cosmetics & Colors in the first nine months of the fiscal year (ending Sept. 30)

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel